Abstract. We describe a case of neonatal diabetes mellitus treated with insulin. The patient was a female with a birth weight of 1590 g, which was small for her gestational age. Although intravenous insulin infusion was started at 48 hours after birth, it was difficult to achieve a good glycemic control, which resulted in poor physical growth in spite of insulin infusion. Continuous subcutaneous insulin infusion (CSII) was started at 86 days after birth. Insulin requirement began to decrease after she reached 1 year of age, and insulin therapy was terminated at 14 months of age. When a VSD patch closure operation was performed at 2 years of age, insulin treatment by CSII was needed for only 10 days. Intrinsic insulin secretion provoked by glucagon was poor at 4 months, but had improved to some extent at 4 years. The patient's physical and neurological development has been normal until now without any diabetic complications. Recently hyperglycemia sometimes has occurred after meals, and her glycosylated hemoglobin has risen to 6.0%. Neonatal diabetes is very rare and most cases are reported to be of a transient type. Careful follow up of the clinical course for a long time and appropriate treatment, including CSII, will be necessary for individual cases.
Introduction
Neonatal diabetes mellitus is reported to be very rare (1) . The incidence has been estimated to be 1 in 500,000 neonates in Germany. Its etiology and long-term clinical course are not well known. In some cases it is very difficult to control blood glucose levels during neonatal and infantile periods. We report a patient with neonatal diabetes treated with insulin and followed up until 5 years of age.
Case Report
The patient was delivered after 36 weeks of gestation with a birth weight of 1590 g, which was small for that gestational age, by cesarean section because of fetal distress. She was the second child of unconsanguineous parents. There was no patient with diabetes mellitus in her family. During pregnancy, the mother was managed carefully due to intrauterine growth retardation and oligohydramnios.
The patient's blood glucose concentration was 46 mg/dl at birth, and intravenous drip infusion of 10% glucose solution was then given. When she was 24 hours old, her blood glucose concentration has risen to 385 mg/dl with mild ketone increase without apparent acidosis. Because of continuous hyperglycemia, an intravenous insulin infusion was started at 48 hours of life. The initial dose of insulin was 0.02 IU/kg/hour. She was also d i a gn o s ed a s h av in g V S D b y u lt r a s o u n d cardiography at 2 days of life and anemia. At 4 days of life she was transferred to our hospital for further treatment. On admission no remarkable abnormal neurological finding was seen except mild irritability. Her blood glucose concentration decreased to 39 mg/dl as a result of insulin therapy, so we stopped insulin infusion and started monitoring her blood glucose level. She had severe anemia, with a hemoglobin value of 6.4 g/dl, and required red blood cell transfusion. There was also mild pancytepenia in laboratory findings on admission (Table 1 ) but the decrease in white blood cells and platelets soon improved, the cause of these remaining unknown. In the first 2 weeks of life, human milk or formula and drip infusion were given. Her blood glucose concentration was controlled to below 200 mg/dl without insulin, but she lost weight steadily, and weighed only 1104 g on the 16th day of life when hyperglycemia above 300 mg/dl occurred again. Intravenous insulin infusion was started again at 3 weeks of life. The insulin requirement dose was 0.15-0.35 IU/kg/ day. We tried to regulate blood glucose, but it remained erratic. Her blood glucose concentration varied widely between about 40 and over 300 mg/ dl in spite of fine adjustment of insulin doses. Her weight gain was very poor (Fig. 1) .
We started continuous subcutaneous insulin infusion, CSII, instead of intravenous insulin infusion, at the 86th day of life. Rapid acting insulin (Novolin R®: 40 IU/ml, Novo Nordisk Pharma Co.), diluted with isotonic saline to a concentration of 1.0 IU/ml, was administered as a basal infusion without bolus infusion before feeding. We used a Nipro SP3HQ® (Nissho-Nipro Ltd. Co.) as an insulin infusion pump. The needle of the pump was inserted into her abdomen or thigh. The blood glucose concentration was checked in blood samples taken from her heels. We tried to keep it between 100 and 250 mg/dl. The continuous basal dose was increased by 10 percent or decreased by 10 percent according to the blood glucose concentration detected by monitoring. The required insulin dose became fairly constant at about 0.1 IU/kg/day within a few weeks, and the patient's glycemic control remained acceptable, which led to increased body weight again. Neither islet cell antibody nor glutamic acid decarboxylase antibody was detected. An intravenous glucagon stimulation test revealed poor ability to secrete insulin from β cells at 4 months of life; the basal C-peptide was 0.66 ng/ml and the peak was 1.29 ng/ml ( Table 2) . Her serum amylase level was normal and no fatty stool was seen during the admission period.
The patient was discharged from our hospital at 6 months of age and treated continuously with insulin by CSII. Her blood glucose concentration was checked by her parents at home. There were no undue restrictions on her lifestyle caused by always having the CSII pump with her. She had some episodes of hyperglycemia on days when she was sick. The basal dose of insulin was increased or a bolus infusion was added at that time. There were no pump troubles, but the patient once had skin infection, with a subcutaneous abscess, at the injection site in her right thigh. The insulin dose was gradually decreased after 1 year, and we stopped CSII when she was 14 months old.
When the patient was 2 years and 3 months old, a VSD patch closure operation was performed. Hyperglycemia occurred again after that, and we treated the patient with insulin by CSII for only 10 days. She has not needed insulin since then.
An intravenous glucagon stimulation test at 4 years and 10 months of age showed that the patient's insulin secretion function was better than in the infantile period (Table 2) .
Glucosuria and hyperglycemia after meals sometimes have recently occurred, and the patient's glycosylated hemoglobin value has increased (Fig. 2) . We have therefore prescribed a diabetic diet of 1440 kcal/day. The patient's physical and neurological development is normal at 5 years of age. 
Discussion
Neonatal diabetes mellitus, which presents hyperglycemia within the first 4 weeks of life and lasts for more than 2 weeks, is a very rare condition. About two-thirds of these cases are transient neonatal diabetes mellitus (TNDM), whereas others are permanent neonatal diabetes mellitus (PNDM) (1, 2) . Both groups generally require insulin treatment. Some cases, at first diagnosed as the transient type, subsequently relapse, so that PNDM is distinguished from TNDM only by their course.
In t h e p res en t c as e, t he p a ti en t ha d hyperglycemia at 24 hours after birth and we started insulin therapy by intravenous infusion at 48 hours. She was small for her gestational age, as is true for many cases of neonatal diabetes (1-3) . She did n ot ha ve an y d etectable rela ted autoimmunity or mitochondrial disorder. Her levels of plasma C-peptide and insulin were low in spite of hyperglycemia at first, and increased later (Table 3) . Her response to the intravenous glucagon stimulation test also improved as she grew (Table 2) . Judging from the clinical course, the case seems to have been a transient type at first, but even after cessation of insulin therapy, hyperglycemia sometimes occurs especially under stress, and her glycosylated hemoglobin increased (Fig. 2) . She does not presently need insulin therapy, and her condition is controlled well only by dietary therapy. We consider that she is a PNDM, although she had an incomplete remission period. On the other hand, recently it is said that intrauterine growth retardation is associated with insulin resistance and an increased risk of developing adult degenerative diseases such as non-insulin dependent diabetes mellitus (4, 5) . Insulin resistance may appear in some PNDM as second diabetes. The patient has sufficient insulin secretion now (Tables 2, 3 ), so we should examine the possibility of early-onset insulin resistance.
Continuous infusions or multiple injections of short-acting insulin and intermediate or longacting insulin have generally been used for neonatal diabetes (2, 6) . It is said that giving appropriate doses of insulin and small gradual changes in doses with frequent blood glucose monitoring are important and safe ways to avoid hypoglycemia during insulin treatment of neonates (2, 6) , but it is very difficult to adequately regulate the metabolic status in some cases by conventional therapy (7) . There are some reports of CSII therapy for brittle diabetes in the early infantile period (8, 9) . In the present case, she should have had daily changes of milk feeding and intravenous nutrition because of such a low-birth weight. Her blood glucose levels also fluctuated widely due to some forms of stress. With i n t r a v e n o u s i n s u l i n i n f u s i o n , a c c u ra t e administration of insulin was sometimes very difficult because of the very small doses and infusion line troubles. The initial insulin treatment was not successful, but the apparent cause is still not known. After the introduction of CSII therapy, the patient fortunately had better glycemic control, with strict medical management and sufficient education of her family. We administered insulin with CSII only by basal infusion without bolus injections before feeding to avoid the risk of brain damage caused by hypoglycemic episodes; so that she did not have severe hypoglycemia during this treatment.
In follow-up examinations at 5 years of age, her physical and neurological development is normal, and there are no diabetic complications such as nephropathy or retinopathy. We are currently considering whether we should treat her with insulin again, or with an oral antidiabetic agent.
In conclusion, sufficient follow-up and appropriate treatment will be necessary for all cases of neonatal diabetes for a long time, and CSII therapy should be considered for britle cases even in the neonatal and infantile periods.
